A Phase II, Multicentre, Open, Randomised, Dose Ranging Study to Investigate the Efficacy of Combination Therapy Containing Dacarbazine (DTIC) Plus Low Dose Interferon Alpha (aIFN) Plus Thymosin a1 Versus Both DTIC Plus Thymosin a1 and DTIC Plus aIFN in Patients With Advanced -Stage Metastatic Malignant Melanoma.

Trial Profile

A Phase II, Multicentre, Open, Randomised, Dose Ranging Study to Investigate the Efficacy of Combination Therapy Containing Dacarbazine (DTIC) Plus Low Dose Interferon Alpha (aIFN) Plus Thymosin a1 Versus Both DTIC Plus Thymosin a1 and DTIC Plus aIFN in Patients With Advanced -Stage Metastatic Malignant Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2010

At a glance

  • Drugs Dacarbazine; Interferon alpha; Thymalfasin
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors sigma-tau SpA
  • Most Recent Events

    • 01 Apr 2010 Results published in JCO.
    • 22 Jun 2009 Additional trial locations, lead trial investigator (Ferraresi V), actual initiation date (July 2002) and official title added as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Actual end date (Sep 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top